DK1840125T3 - Mellemprodukter til fremstilling af dioxan-2-alkylcarbamater - Google Patents

Mellemprodukter til fremstilling af dioxan-2-alkylcarbamater

Info

Publication number: DK1840125T3
Authority: DK; Denmark
Prior art keywords: alkylcarbamates; intermediates; dioxane; preparation
Prior art date: 2002-08-29

Application number

DK07013954T

Other languages

English (en)

Inventor

Ahmed Abouabdellah

Michele Bas

Gihad Dargazanli

Christian Hoornaert

Adrien Tak Li

Florence Medaisko

Original Assignee

Sanofi Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-29

Filing date

2003-08-27

Publication date

2009-11-09

2003-08-27 Application filed by Sanofi Aventis filed Critical Sanofi Aventis

2009-11-09 Application granted granted Critical

2009-11-09 Publication of DK1840125T3 publication Critical patent/DK1840125T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Virology (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Dermatology (AREA)
Tropical Medicine & Parasitology (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Molecular Biology (AREA)
Otolaryngology (AREA)
Transplantation (AREA)
Anesthesiology (AREA)

DK07013954T 2002-08-29 2003-08-27 Mellemprodukter til fremstilling af dioxan-2-alkylcarbamater DK1840125T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0210707A FR2843964B1 (fr)	2002-08-29	2002-08-29	Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
PCT/FR2003/002590 WO2004020430A2 (fr)	2002-08-29	2003-08-27	Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique

Publications (1)

Publication Number	Publication Date
DK1840125T3 true DK1840125T3 (da)	2009-11-09

Family

ID=31502974

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK07013954T DK1840125T3 (da)	2002-08-29	2003-08-27	Mellemprodukter til fremstilling af dioxan-2-alkylcarbamater
DK03758282T DK1537096T3 (da)	2002-08-29	2003-08-27	Derivater af dioxan-2-alkylcarbamater, fremstilling og terapeutisk anvendelse heraf

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK03758282T DK1537096T3 (da)	2002-08-29	2003-08-27	Derivater af dioxan-2-alkylcarbamater, fremstilling og terapeutisk anvendelse heraf

Country Status (35)

Country	Link
US (4)	US7119116B2 (da)
EP (2)	EP1537096B1 (da)
JP (2)	JP4585854B2 (da)
KR (2)	KR101051192B1 (da)
CN (3)	CN101906071A (da)
AR (1)	AR041053A1 (da)
AT (2)	ATE409184T1 (da)
AU (1)	AU2003274292B2 (da)
BR (1)	BR0313846A (da)
CA (2)	CA2496040C (da)
CO (1)	CO5700820A2 (da)
CY (2)	CY1108792T1 (da)
DE (2)	DE60328138D1 (da)
DK (2)	DK1840125T3 (da)
EA (1)	EA008218B1 (da)
ES (2)	ES2329181T3 (da)
FR (1)	FR2843964B1 (da)
HK (2)	HK1074445A1 (da)
HR (2)	HRP20050190B1 (da)
IL (1)	IL166882A (da)
IS (1)	IS2733B (da)
MA (1)	MA27390A1 (da)
ME (2)	MEP24208A (da)
MX (1)	MXPA05002319A (da)
NO (2)	NO331165B1 (da)
NZ (1)	NZ538404A (da)
PL (1)	PL209339B1 (da)
PT (2)	PT1537096E (da)
RS (2)	RS20100169A (da)
SI (2)	SI1537096T1 (da)
TN (1)	TNSN05057A1 (da)
TW (2)	TWI337606B (da)
UA (1)	UA82847C2 (da)
WO (1)	WO2004020430A2 (da)
ZA (1)	ZA200501537B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2843964B1 (fr) *	2002-08-29	2004-10-01	Sanofi Synthelabo	Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
WO2004033422A2 (en) *	2002-10-07	2004-04-22	The Regents Of The University Of California	Modulation of anxiety through blockade of anandamide hydrolysis
FR2854633B1 (fr) *	2003-05-07	2005-06-24	Sanofi Synthelabo	Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique
FR2865205B1 (fr) *	2004-01-16	2006-02-24	Sanofi Synthelabo	Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique
FR2866888B1 (fr) *	2004-02-26	2006-05-05	Sanofi Synthelabo	Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique
FR2866886B1 (fr)	2004-02-26	2007-08-31	Sanofi Synthelabo	Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique
FR2866885B1 (fr) *	2004-02-26	2007-08-31	Sanofi Synthelabo	Derives de piperidinylalkylcarbamates, leur prepation et leur application en therapeutique
FR2866884B1 (fr) *	2004-02-26	2007-08-31	Sanofi Synthelabo	Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique
US7269708B2 (en) *	2004-04-20	2007-09-11	Rambus Inc.	Memory controller for non-homogenous memory system
WO2005115370A2 (en) *	2004-04-23	2005-12-08	The Regents Of The University Of California	Compounds and methods for treating non-inflammatory pain using pparalpha agonists
DE102004039326A1 (de) *	2004-08-12	2006-02-16	Abbott Gmbh & Co. Kg	Neue medizinische Verwendungen und Verfahren
ES2433290T3 (es)	2005-02-17	2013-12-10	Astellas Pharma Inc.	Derivados de piperazina para el tratamiento de la incontinencia urinaria y el dolor
FR2885364B1 (fr) *	2005-05-03	2007-06-29	Sanofi Aventis Sa	Derives d'alkyl-, alkenyl-et alkynylcarbamates, leur preparation et leur application en therapeutique
EP2054055A2 (en) *	2006-08-18	2009-05-06	N.V. Organon	Combination faah inhibitor and analgesic, anti-inflammatory or anti-pyretic agent
WO2008030752A2 (en) *	2006-09-07	2008-03-13	N.V. Organon	Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo
WO2008042892A2 (en) *	2006-10-02	2008-04-10	N.V. Organon	Fatty acid amide hydrolase inhibitors for energy metabolism disorders
WO2008063714A1 (en) *	2006-11-20	2008-05-29	N.V. Organon	Metabolically-stabilized inhibitors of fatty acid amide hydrolase
US8207226B1 (en)	2008-06-03	2012-06-26	Alcon Research, Ltd.	Use of FAAH antagonists for treating dry eye and ocular pain
FR2941696B1 (fr) *	2009-02-05	2011-04-15	Sanofi Aventis	Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
TW201044234A (en) *	2009-06-08	2010-12-16	Chunghwa Picture Tubes Ltd	Method of scanning touch panel
WO2011030798A1 (ja)	2009-09-09	2011-03-17	大日本住友製薬株式会社	８－オキソジヒドロプリン誘導体
US8274566B2 (en) *	2009-10-09	2012-09-25	John Mezzalingua Associates, Inc.	Modulation analyzer and level measurement device
EP2545915A1 (en)	2011-07-11	2013-01-16	Sanofi	2-amino-2-oxoethyl trans-3-[5-(6-methoxy-naphtalen-1-yl)-1,3-dioxan-2-yl]propyl-carbamate for use in the treatment of persistent cancer pain
EP2545914A1 (en)	2011-07-11	2013-01-16	Sanofi	2-amino-2-oxoethyl trans-3-[5-(6-methoxy-naphtalen-1-yl)-1,3-dioxan-2-yl]propyl-carbamate for use in the treatment of persistent cancer pain
PE20141702A1 (es) *	2012-01-06	2014-11-19	Abide Therapeutics Inc	Compuestos de carbamato y preparacion y uso de los mismos
CN114835726B (zh) *	2022-03-24	2024-01-26	上海诺精生物科技有限公司	一类抑制肿瘤细胞干性的化合物及用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2064057T3 (es) *	1990-06-15	1995-01-16	Synthelabo	Unos derivados de 2-(aminoalquil)-5-(arilalquil)-1,3-dioxanos, su preparacion y su aplicacion en terapeutica.
US5173506A (en) *	1990-08-16	1992-12-22	Schering Corporation	N-(mercaptoalkyl)ureas and carbamates
FR2742152B1 (fr) *	1995-12-06	1998-01-16	Synthelabo	Derives de 5-naphtalen-1-yl-1,3-dioxanes, leur preparation et leur application en therapeutique
AT403579B (de) *	1995-12-07	1998-03-25	Agrolinz Melamin Gmbh	Verfahren zur herstellung von hochreinem melamin
AR012908A1 (es)	1997-06-05	2000-11-22	Vanmechelen Eugeen	Un compuesto derivado de 5-naftalen-1-il-1,3-dioxano bajo la forma de estereoisomero puro o de mezcla de estereoisomeros, medicamento que consisteen dicho compuesto, y composicion farmaceutica que contiene a dicho compuesto
CA2328990C (en) *	1998-04-16	2011-01-11	Texas Biotechnology Corporation	N,n-disubstituted amides that inhibit the binding of integrins to their receptors
FR2816938B1 (fr)	2000-11-22	2003-01-03	Sanofi Synthelabo	Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
FR2843964B1 (fr) *	2002-08-29	2004-10-01	Sanofi Synthelabo	Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique

2002
- 2002-08-29 FR FR0210707A patent/FR2843964B1/fr not_active Expired - Fee Related
2003
- 2003-08-26 AR ARP030103063A patent/AR041053A1/es active IP Right Grant
- 2003-08-27 RS RSP-2010/0169A patent/RS20100169A/en unknown
- 2003-08-27 PT PT03758282T patent/PT1537096E/pt unknown
- 2003-08-27 UA UAA200501766A patent/UA82847C2/uk unknown
- 2003-08-27 AT AT03758282T patent/ATE409184T1/de active
- 2003-08-27 PL PL375753A patent/PL209339B1/pl unknown
- 2003-08-27 ZA ZA200501537A patent/ZA200501537B/en unknown
- 2003-08-27 DK DK07013954T patent/DK1840125T3/da active
- 2003-08-27 ES ES07013954T patent/ES2329181T3/es not_active Expired - Lifetime
- 2003-08-27 KR KR1020057003244A patent/KR101051192B1/ko not_active IP Right Cessation
- 2003-08-27 CA CA2496040A patent/CA2496040C/en not_active Expired - Fee Related
- 2003-08-27 RS YUP-2005/0182A patent/RS51085B/sr unknown
- 2003-08-27 PT PT07013954T patent/PT1840125E/pt unknown
- 2003-08-27 JP JP2004532233A patent/JP4585854B2/ja not_active Expired - Fee Related
- 2003-08-27 MX MXPA05002319A patent/MXPA05002319A/es active IP Right Grant
- 2003-08-27 AU AU2003274292A patent/AU2003274292B2/en not_active Ceased
- 2003-08-27 AT AT07013954T patent/ATE434598T1/de active
- 2003-08-27 SI SI200331438T patent/SI1537096T1/sl unknown
- 2003-08-27 ES ES03758282T patent/ES2312808T3/es not_active Expired - Lifetime
- 2003-08-27 CA CA2700319A patent/CA2700319C/en not_active Expired - Fee Related
- 2003-08-27 KR KR1020107028059A patent/KR101139160B1/ko not_active IP Right Cessation
- 2003-08-27 EP EP03758282A patent/EP1537096B1/fr not_active Expired - Lifetime
- 2003-08-27 CN CN2010101829555A patent/CN101906071A/zh active Pending
- 2003-08-27 EP EP07013954A patent/EP1840125B1/fr not_active Expired - Lifetime
- 2003-08-27 CN CN200810186321XA patent/CN101445504B/zh not_active Expired - Fee Related
- 2003-08-27 DK DK03758282T patent/DK1537096T3/da active
- 2003-08-27 SI SI200331666T patent/SI1840125T1/sl unknown
- 2003-08-27 CN CNB038241056A patent/CN100491368C/zh not_active Expired - Fee Related
- 2003-08-27 DE DE60328138T patent/DE60328138D1/de not_active Expired - Lifetime
- 2003-08-27 DE DE60323754T patent/DE60323754D1/de not_active Expired - Lifetime
- 2003-08-27 ME MEP-242/08A patent/MEP24208A/xx unknown
- 2003-08-27 BR BR0313846-1A patent/BR0313846A/pt not_active Application Discontinuation
- 2003-08-27 NZ NZ538404A patent/NZ538404A/en not_active IP Right Cessation
- 2003-08-27 WO PCT/FR2003/002590 patent/WO2004020430A2/fr active Application Filing
- 2003-08-27 EA EA200500268A patent/EA008218B1/ru not_active IP Right Cessation
- 2003-08-28 TW TW096123915A patent/TWI337606B/zh not_active IP Right Cessation
- 2003-08-28 TW TW092123746A patent/TWI294878B/zh not_active IP Right Cessation
2004
- 2004-03-11 ME MEP-2008-242A patent/ME00108B/me unknown
2005
- 2005-02-14 IL IL166882A patent/IL166882A/en not_active IP Right Cessation
- 2005-02-17 IS IS7699A patent/IS2733B/is unknown
- 2005-02-22 US US11/062,541 patent/US7119116B2/en not_active Expired - Lifetime
- 2005-02-24 CO CO05017682A patent/CO5700820A2/es active IP Right Grant
- 2005-02-25 NO NO20051051A patent/NO331165B1/no not_active IP Right Cessation
- 2005-02-25 TN TNP2005000057A patent/TNSN05057A1/fr unknown
- 2005-02-28 HR HRP20050190AA patent/HRP20050190B1/hr not_active IP Right Cessation
- 2005-02-28 MA MA28125A patent/MA27390A1/fr unknown
- 2005-09-23 HK HK05108400A patent/HK1074445A1/xx not_active IP Right Cessation
- 2005-09-23 HK HK08101677.0A patent/HK1108157A1/xx not_active IP Right Cessation
2006
- 2006-06-28 US US11/426,964 patent/US20060247290A1/en not_active Abandoned
2008
- 2008-12-12 CY CY20081101445T patent/CY1108792T1/el unknown
2009
- 2009-05-14 HR HRP20090270AA patent/HRP20090270B1/hr not_active IP Right Cessation
- 2009-07-28 US US12/510,326 patent/US7777057B2/en not_active Expired - Fee Related
- 2009-09-24 CY CY20091100995T patent/CY1109441T1/el unknown
2010
- 2010-06-18 JP JP2010139427A patent/JP5244863B2/ja not_active Expired - Fee Related
- 2010-07-12 US US12/834,268 patent/US8119687B2/en not_active Expired - Fee Related
2011
- 2011-04-15 NO NO20110598A patent/NO335866B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
CN101906071A (zh)	2010-12-08
AR041053A1 (es)	2005-04-27
PT1840125E (pt)	2009-09-29
MA27390A1 (fr)	2005-06-01
NZ538404A (en)	2007-07-27
ME00108B (me)	2010-10-10
JP4585854B2 (ja)	2010-11-24
JP2010248218A (ja)	2010-11-04
ATE409184T1 (de)	2008-10-15
CA2700319A1 (en)	2004-03-11
CN101445504A (zh)	2009-06-03
WO2004020430A2 (fr)	2004-03-11
NO20110598L (no)	2005-03-29
HK1108157A1 (en)	2008-05-02
AU2003274292B2 (en)	2009-05-28
PL209339B1 (pl)	2011-08-31
RS20050182A (en)	2007-09-21
HK1074445A1 (en)	2005-11-11
CN1777595A (zh)	2006-05-24
PT1537096E (pt)	2008-12-11
US20090286868A1 (en)	2009-11-19
ATE434598T1 (de)	2009-07-15
EP1537096A2 (fr)	2005-06-08
ES2312808T3 (es)	2009-03-01
SI1537096T1 (sl)	2009-02-28
TWI337606B (en)	2011-02-21
EA008218B1 (ru)	2007-04-27
US20060247290A1 (en)	2006-11-02
HRP20050190A2 (en)	2005-10-31
CA2496040C (en)	2011-04-05
HRP20050190B1 (hr)	2013-10-25
UA82847C2 (en)	2008-05-26
CA2700319C (en)	2012-07-17
TNSN05057A1 (fr)	2007-05-14
CA2496040A1 (en)	2004-03-11
EP1840125B1 (fr)	2009-06-24
IS2733B (is)	2011-04-15
CN101445504B (zh)	2010-12-29
PL375753A1 (en)	2005-12-12
MXPA05002319A (es)	2005-06-08
SI1840125T1 (sl)	2009-12-31
FR2843964B1 (fr)	2004-10-01
KR20050059108A (ko)	2005-06-17
KR20100134807A (ko)	2010-12-23
KR101139160B1 (ko)	2012-04-26
ES2329181T3 (es)	2009-11-23
RS51085B (sr)	2010-10-31
CO5700820A2 (es)	2006-11-30
IL166882A (en)	2010-12-30
KR101051192B1 (ko)	2011-07-21
JP5244863B2 (ja)	2013-07-24
EP1840125A3 (fr)	2007-11-21
DE60323754D1 (de)	2008-11-06
DK1537096T3 (da)	2009-02-02
US7119116B2 (en)	2006-10-10
TWI294878B (en)	2008-03-21
AU2003274292A1 (en)	2004-03-19
NO20051051L (no)	2005-03-29
BR0313846A (pt)	2005-09-27
US7777057B2 (en)	2010-08-17
EP1840125A2 (fr)	2007-10-03
NO331165B1 (no)	2011-10-24
TW200738667A (en)	2007-10-16
TW200422294A (en)	2004-11-01
WO2004020430A3 (fr)	2004-04-22
US8119687B2 (en)	2012-02-21
DE60328138D1 (de)	2009-08-06
CN100491368C (zh)	2009-05-27
CY1109441T1 (el)	2014-08-13
US20100280076A1 (en)	2010-11-04
CY1108792T1 (el)	2014-04-09
US20050182130A1 (en)	2005-08-18
JP2005539045A (ja)	2005-12-22
EA200500268A1 (ru)	2005-10-27
MEP24208A (en)	2010-06-10
HRP20090270A2 (hr)	2009-09-30
ZA200501537B (en)	2006-10-25
NO335866B1 (no)	2015-03-09
EP1537096B1 (fr)	2008-09-24
HRP20090270B1 (hr)	2015-12-04
FR2843964A1 (fr)	2004-03-05
IS7699A (is)	2005-02-17
RS20100169A (en)	2011-04-30

Publication	Publication Date	Title
DK1840125T3 (da)	2009-11-09	Mellemprodukter til fremstilling af dioxan-2-alkylcarbamater
DK1575416T3 (da)	2014-01-13	Fremgangsmåder til diagnosticering af præeklampsi
DK1828164T3 (da)	2008-12-08	Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK1778668T3 (da)	2013-09-30	Fremgangsmåde til fremstilling af dihydropteridion
DK1348473T3 (da)	2007-05-14	Elementsæt til samling af strukturer
DK1504126T3 (da)	2014-06-10	Fremgangsmåde til regulering af genekspression
DK1277722T3 (da)	2005-04-25	Fremgangsmåde til fremstilling af methanol
DK1611108T3 (da)	2011-10-10	Fremgangsmåde til fremstilling af telmisartan
DK1546122T3 (da)	2008-03-03	Fremgangsmåde til fremstilling af valsartan
DK1587542T3 (da)	2012-07-30	Anvendelse af anti-CD100-antistoffer
DK1407037T3 (da)	2006-05-22	Fremgangsmåde til fremstilling af tagatose
DK1516540T3 (da)	2012-11-26	Anvendelse af vitamin D-forbindelser
DK1578731T3 (da)	2010-02-15	Fremgangsmåde til fremstilling af pyrimidinforbindelser
DK1401277T3 (da)	2007-08-27	Aminoacetonitrilforbindelser til bekæmpelse af endoparasitter
DK1572613T3 (da)	2006-12-18	Fremgangsmåde til fremstilling af benzophenoner
DK1678135T3 (da)	2009-09-07	Fremgangsm de til fremstilling af n-amino-substituerede hetorocykliske forbindelser
DK1575941T3 (da)	2012-07-09	Fremgangsmåde til fremstilling af (S)-pantoprazol
DK1519928T3 (da)	2014-08-04	Fremgangsmåde til fremstilling af heterocykliske fluoralkenylsulfoner
DK1831223T3 (da)	2013-06-10	Fremgangsmåde til fremstilling af L-biopterin
DK1511724T3 (da)	2014-06-16	Fremgangsmåde til fremstilling af thioalkylaminderivater
DK3332789T3 (da)	2022-07-11	Cladribinkur til behandling af multipel sklerose
DK1503995T3 (da)	2008-04-21	Fremgangsmåde til fremstilling af substituerede phenylsulfonylurinstoffer
DK1692137T3 (da)	2007-04-30	Fremgangsmåde til fremstilling af tubulinininhibitorer
DK1519936T3 (da)	2008-03-03	Fremgangsmåde til fremstilling af nevirapin
ITMI20031994A1 (it)	2005-04-16	Procedimento per la preparazione di fludarabina fosfato